CORDIS
EU research results

CORDIS

English EN
Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production

Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production

Objective

iConsensus will provide innovative analytical, hardware, software and high-throughput (HTP) solutions for the development, monitoring and control of mammalian cell cultivation process producing biopharmaceuticals. iConsensus will develop an analytical platform with on-line/at-line sensors and detection methods measuring multiple factors in the cell culture and the produced biopharmaceutical. Under advanced data management, the analytical platform will be integrated in new micro-bioreactors for HTP screening on one hand and in classical stirred tank vessel bioreactor on the other hand. Based on the analytical information, feedback control will be applied. When deemed suitable, implementation in GMP production of the sensing and control tools will be carried on.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KUNGLIGA TEKNISKA HOEGSKOLAN

Address

Brinellvagen 8
100 44 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 387 000

Participants (18)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITE DE MONS

Belgium

EU Contribution

€ 300 000

PRESENS PRECISION SENSING GMBH

Germany

EU Contribution

€ 454 000

M2P-LABS GMBH

Germany

EU Contribution

€ 300 000

UNIVERSITAET HOHENHEIM

Germany

EU Contribution

€ 355 500

IPRATECH SA

Belgium

EU Contribution

€ 150 000

KANTISTO BV

Netherlands

EU Contribution

€ 308 500

IPRASENSE

France

EU Contribution

€ 71 000

RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN

Germany

EU Contribution

€ 374 000

MICRONIT MICROTECHNOLOGIES BV

Netherlands

EU Contribution

€ 650 000

PAIA BIOTECH GMBH

Germany

EU Contribution

€ 250 000

SVANHOLM.COM APS

Denmark

EU Contribution

€ 100 000

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

BAYER AKTIENGESELLSCHAFT

Germany

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

UCB BIOPHARMA SPRL

Belgium

PFIZER LIMITED

United Kingdom

RENTSCHLER BIOPHARMA SE

Germany

SYNTHON BIOPHARMACEUTICALS BV

Netherlands

Project information

Grant agreement ID: 777397

Status

Ongoing project

  • Start date

    1 May 2018

  • End date

    30 April 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 9 400 000

  • EU contribution

    € 4 700 000

Coordinated by:

KUNGLIGA TEKNISKA HOEGSKOLAN

Sweden